Reagan Barnett, PhD
@genesdontfitMedical Science Liaison @GuardantHealth. #coloncancer & #LynchSyndrome at 22. Interests in #genetics 🧬 & #datascience 📊 Closet writer, amateur photographer.
Similar User
@Alive_And_Kickn
@BRCAresponder
@CancerBeGlammed
@HHampel1
@MyGeneCounsel
@womenofteal
@fflcancersprt
@karenBRCAMTL
@ABumRap
@drwilliamharb
@DanielleisB
@onco_pedia
@alkhatabiheba
@LguzzardiM
@OncoPolmoneIEO
We look forward to sharing data at #ESMO24, highlighting the critical role liquid biopsy plays in informing therapy selection and the strong performance of our precision oncology technology in multiple advanced tumor types. Press release & presentation details:…
Our health outcomes study, the CAN-SCREEN model, has been accepted for publication in the @JME_Journal More details: bit.ly/3SsSAqb
Our Shield blood test is now covered by #Medicare and is commercially available in the U.S. as the first FDA-approved blood test for primary #ColorectalCancer screening.
Our COSMOS study was published today in Clinical Cancer Research, a journal of the @CCR_AACR The results validate the utility of our Guardant Reveal blood test for predicting #ColorectalCancer recurrence without the complexity of prior tissue analysis. Read more:…
We’re changing the game for #ColorectalCancer screening w/ the FDA approval of Shield, our blood test for people age 45+ at average risk. With Shield, we aim to get more people tested & catch more cancers early, when they’re most treatable. Read more: bit.ly/3WnfKzi
Today we announced a major upgrade to our market-leading Guardant360 test. It now covers 10x more genomic biomarkers, including all guideline-recommended ones across advanced solid tumors, and quantifies tumor burden with 10x higher sensitivity. Details: bit.ly/3Yc68d9
Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers academic.oup.com/oncolo/article… @SteveMaronMD @KlempnerSam @genesdontfit @LDrusbosky @GuardantHealth #GEAs #ctDNA
We have launched our upgraded Guardant360 TissueNext test featuring an expanded gene panel of 498 biomarkers and a faster turnaround time for results. More details: investors.guardanthealth.com/press-releases…
Ph 3 Checkmate 8HW update from Dr. Lenz @uscnorris re: 👉🏻 Nivo/ipi vs Nivo vs Chemo in MSI-H met #colorectalcancer (vs chemo only at this time) 👉🏻 Primary endpoint = PFS 👉🏻2yr PFS= 72% HR=0.21 👉🏻46% crossover with PFS2 (83% vs 52%) #ASCO24 @asco #cancer #canceresearch
Great to meet with @NicTarantino22 @genesdontfit @cristin_oneal and @ApurvaDixit12 to discuss collaborations with @GuardantHealth @BrownUCancer @LifespanHlthSys @BrownMedicine @WIN_Consortium #LegorretaCancerCenter there is much to do in the field of precision oncology to move…
Attending ASCO24? I’d love to chat with you about all things liquid biopsy and methylation - @genesdontfit oncodaily.com/74188.html #ASCO24 #Cancer #CRC #Biopsy #Methylation #OncoDaily #Oncology
Dear Colleagues, The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 for GI Cancers This List Curated by: @dr_yakupergun 🇹🇷 @DenizCanGuven1 🇹🇷 @heinrich_kat 🇩🇪 and @weoncologists 🇺🇸 with OncoAlert GI Faculty @BenWestphalen 🇩🇪 1- A phase…
Join us at #ASCO24 as we present data highlighting important developments in #CancerCare using liquid biopsy to identify epigenomic biomarkers. Visit booth 28115 to learn more. Full release: investors.guardanthealth.com/press-releases…
Attending #ASCO24? I’d love to chat with you about all things #liquidbiopsy and #methylation! And of course, #CRC :)
The moment in the room when the FDA advisory committee voted 7-2 to approve @GuardantHealth Shield for #ColorectalCancer screening. This was a big day, and hopefully many more pts will soon have another screening option!
T-10 days for @ASCO #ASCO24! Plan your meeting and be ready to get lost in #data and McCormick! Well, 1️⃣ of them we can prepare for! 👀 floorplan for McCormick at #ASCO24! 🗺️ Check out where all the exciting exhibit booths! 🎪 bit.ly/3WRRV4E @OncoAlert @HemOncFellows
Congrats to everyone at Guardant who contributed to Shield! Great progress forward for patients.
Today the FDA’s Medical Devices Advisory Committee panel strongly recommended FDA approval of our Shield blood test for #ColorectalCancer screening in adults age 45 and older who are at average risk for the disease. Full release: investors.guardanthealth.com/press-releases…
Today the FDA’s Medical Devices Advisory Committee panel strongly recommended FDA approval of our Shield blood test for #ColorectalCancer screening in adults age 45 and older who are at average risk for the disease. Full release: investors.guardanthealth.com/press-releases…
ICYMI: UC San Diego Professor of Medicine @samirguptaGI discusses how new screening options, such as our Shield blood test, could help elevate #ColorectalCancer screening rates, identify treatable cancers, and reduce the number of deaths from the disease.
United States Trends
- 1. Good Sunday 58,8 B posts
- 2. #chillguy 27,5 B posts
- 3. #sundayvibes 6.012 posts
- 4. Chuck Woolery 8.331 posts
- 5. #AskZB N/A
- 6. #IPLAuction2025 47,9 B posts
- 7. #SundayMotivation 2.645 posts
- 8. Love Connection 5.427 posts
- 9. Bama 38,8 B posts
- 10. Wheel of Fortune 4.086 posts
- 11. Lakers 41,8 B posts
- 12. Blessed Sunday 15 B posts
- 13. Auburn 36,4 B posts
- 14. F-35 22,6 B posts
- 15. Pant 73 B posts
- 16. Christ Jesus 49,6 B posts
- 17. Max Verstappen 145 B posts
- 18. Happy Birthday Anne N/A
- 19. Ferrari 94,8 B posts
- 20. Lawrence Welk N/A
Who to follow
-
AliveAndKickn
@Alive_And_Kickn -
Amy Byer Shainman
@BRCAresponder -
Cancer Be Glammed
@CancerBeGlammed -
Heather Hampel
@HHampel1 -
My Gene Counsel
@MyGeneCounsel -
Dee Sparacio
@womenofteal -
Friend for Life
@fflcancersprt -
Karen Lazarovitz
@karenBRCAMTL -
Anal Cancer
@ABumRap -
Dr. William Harb
@drwilliamharb -
Danielle Ripley-Burgess
@DanielleisB -
Oncopedia
@onco_pedia -
Heba alkhatabi
@alkhatabiheba -
Lisa M Guzzardi, RN
@LguzzardiM -
OncoPolmoneIEO
@OncoPolmoneIEO
Something went wrong.
Something went wrong.